Role of vitamin D supplementation in the management of musculoskeletal diseases: update from an European Society of Clinical and Economical Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) working group.

Détails

Ressource 1Télécharger: 36287325_BIB_E2F9D1D0D265.pdf (1048.24 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_E2F9D1D0D265
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Role of vitamin D supplementation in the management of musculoskeletal diseases: update from an European Society of Clinical and Economical Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) working group.
Périodique
Aging clinical and experimental research
Auteur⸱e⸱s
Chevalley T., Brandi M.L., Cashman K.D., Cavalier E., Harvey N.C., Maggi S., Cooper C., Al-Daghri N., Bock O., Bruyère O., Rosa M.M., Cortet B., Cruz-Jentoft A.J., Cherubini A., Dawson-Hughes B., Fielding R., Fuggle N., Halbout P., Kanis J.A., Kaufman J.M., Lamy O., Laslop A., Yerro MCP, Radermecker R., Thiyagarajan J.A., Thomas T., Veronese N., de Wit M., Reginster J.Y., Rizzoli R.
ISSN
1720-8319 (Electronic)
ISSN-L
1594-0667
Statut éditorial
Publié
Date de publication
11/2022
Peer-reviewed
Oui
Volume
34
Numéro
11
Pages
2603-2623
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Vitamin D is a key component for optimal growth and for calcium-phosphate homeostasis. Skin photosynthesis is the main source of vitamin D. Limited sun exposure and insufficient dietary vitamin D supply justify vitamin D supplementation in certain age groups. In older adults, recommended doses for vitamin D supplementation vary between 200 and 2000 IU/day, to achieve a goal of circulating 25-hydroxyvitamin D (calcifediol) of at least 50 nmol/L. The target level depends on the population being supplemented, the assessed system, and the outcome. Several recent large randomized trials with oral vitamin D regimens varying between 2000 and 100,000 IU/month and mostly conducted in vitamin D-replete and healthy individuals have failed to detect any efficacy of these approaches for the prevention of fracture and falls. Considering the well-recognized major musculoskeletal disorders associated with severe vitamin D deficiency and taking into account a possible biphasic effects of vitamin D on fracture and fall risks, an European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) working group convened, carefully reviewed, and analyzed the meta-analyses of randomized controlled trials on the effects of vitamin D on fracture risk, falls or osteoarthritis, and came to the conclusion that 1000 IU daily should be recommended in patients at increased risk of vitamin D deficiency. The group also addressed the identification of patients possibly benefitting from a vitamin D loading dose to achieve early 25-hydroxyvitamin D therapeutic level or from calcifediol administration.
Mots-clé
Humans, Aged, Calcifediol, Vitamin D, Vitamin D Deficiency/epidemiology, Osteoporosis/drug therapy, Vitamins/therapeutic use, Bone Density Conservation Agents/therapeutic use, Dietary Supplements/adverse effects, Fractures, Bone/prevention & control, Osteoarthritis/drug therapy, Falls, Fragility fracture, Osteoarthritis
Pubmed
Web of science
Open Access
Oui
Création de la notice
02/11/2022 9:21
Dernière modification de la notice
23/01/2024 8:36
Données d'usage